'This is the most promising medication we've had so far in terms of slowing rate of decline.'
'This is the most promising medication we've had so far in terms of slowing rate of decline.' ()
UConn Health is now offering the drug lecanemab to patients with mild signs of dementia. In clinical trials it was shown to slow the progression of Alzheimer's. The memory assessment team at the UConn Center on Aging consists of multidisciplinary experts who monitor and guide patients through the treatment process. The drug may not be a cure for Alzheimer's but for patients like Eric Jackson, it offers the chance to remain independent longer.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
